Does a high apolipoprotein B or LDL particle number raise cardiovascular risk when LDL-C is normal?

Diagnostic utility of ApoB stoichiometry

Apolipoprotein B (ApoB) serves as a direct, precise biochemical surrogate for the total count of circulating atherogenic lipoprotein particles. This utility is rooted in a strict 1:1 stoichiometry, where each atherogenic particle—including very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL), and lipoprotein(a)—possesses exactly one molecule of ApoB. While traditional low-density lipoprotein cholesterol (LDL-C) measures only the cholesterol mass within these particles, which can vary widely depending on particle size and lipid packing, ApoB concentrations directly reflect absolute particle numbers. Consequently, ApoB is highly correlated with nuclear magnetic resonance (NMR)-measured LDL particle number ($r \approx 0.85$ to $0.95$), serving as a reliable clinical alternative.

Cardiovascular risk in lipid discordance

When LDL-C is normal but ApoB or LDL particle number is high—a state of lipid discordance—cardiovascular risk is significantly higher than LDL-C alone suggests. This discordance typically arises when a patient has a high concentration of small, dense, cholesterol-depleted LDL particles, a phenotype highly prevalent in metabolic syndrome, insulin resistance, and elevated triglycerides. Large-scale cohort data, including analyses from the UK Biobank, demonstrate that individuals with discordantly high ApoB relative to LDL-C face an 11% to 15% increased risk of major adverse cardiovascular events (MACE). Part of this excess risk is mediated by elevated VLDL particles and triglycerides, which account for approximately 25.5% and 26.6% of the excess MACE risk in discordant patients, respectively.

Bottom line

When LDL cholesterol is normal but ApoB or LDL particle number is high, cardiovascular risk is elevated beyond what traditional lipid panels suggest. Measuring ApoB provides a more accurate assessment of the true atherogenic particle burden, making it an essential tool for identifying hidden residual risk in patients with metabolic risk factors.